We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+67.05%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$486M
AUM Growth
+$109M
Cap. Flow
+$86.4M
Cap. Flow %
17.77%
Top 10 Hldgs %
56.66%
Holding
71
New
17
Increased
8
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.6M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$15.3M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$12.9M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$8.22M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.49M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.5M
2
CELG
Celgene Corp
CELG
+$17.2M
3
OMER icon
Omeros
OMER
+$8.05M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$7.2M
5
MRK icon
Merck
MRK
+$5.79M

Sector Composition

Rank Sector Weight
1 Healthcare 79.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
1
Puma Biotechnology
PBYI
$402M
$121M 24.9%
507,500
+300,000
+145% +$61.6M
RCPT
2
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$46.5M 9.56%
748,700
+269,900
+56% +$12.9M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$16.2B
$16.1M 3.3%
100,000
– –
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$15.2M 3.12%
1,500,000
-300,000
-17% -$2.91M
KERX
5
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$13.8M 2.83%
+1,000,000
New +$15.3M
KPTI icon
6
Karyopharm Therapeutics
KPTI
$159M
$13.5M 2.77%
25,667
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$18.7B
$13.3M 2.74%
850,000
+550,000
+183% +$8.22M
ARWR icon
8
Arrowhead Research
ARWR
$12.3B
$13.3M 2.73%
900,000
– –
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$12.1M 2.49%
400,000
+200,000
+100% +$5.63M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.35B
$10.8M 2.21%
1,100,000
-68,000
-6% -$833K
AKBA icon
11
Akebia Therapeutics
AKBA
$362M
$8.85M 1.82%
400,000
– –
TPST icon
12
Tempest Therapeutics
TPST
$13.8M
$8.57M 1.76%
+176
New +$6.17M
TSRO
13
DELISTED
TESARO, Inc.
TSRO
$8.08M 1.66%
300,000
– –
DXCM icon
14
DexCom
DXCM
$28.8B
$8M 1.65%
800,000
– –
BMY icon
15
Bristol-Myers Squibb
BMY
$132B
$7.68M 1.58%
+150,000
New +$7.49M
OMER icon
16
Omeros
OMER
$863M
$6.97M 1.43%
547,900
-575,100
-51% -$8.05M
CMRX
17
DELISTED
Chimerix, Inc.
CMRX
$6.91M 1.42%
250,000
-50,000
-17% -$1.21M
GEVA
18
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$6.88M 1.41%
+100,000
New +$7.16M
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.79M 1.4%
120,000
– –
NVAX icon
20
Novavax
NVAX
$1.22B
$6.25M 1.29%
75,000
– –
AGIO icon
21
Agios Pharmaceuticals
AGIO
$1.95B
$6.13M 1.26%
+100,000
New +$4.31M
HRTX icon
22
Heron Therapeutics
HRTX
$94.1M
$5.83M 1.2%
700,000
– –
ARDX icon
23
Ardelyx
ARDX
$1.25B
$5.52M 1.14%
+388,700
New +$5.62M
PTCT icon
24
PTC Therapeutics
PTCT
$6.26B
$5.5M 1.13%
125,000
-25,000
-17% -$782K
TLPH icon
25
Talphera
TLPH
$70.1M
$5.49M 1.13%
50,000
+15,000
+43% +$2.36M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Cormorant Asset Management held 71 positions worth $486M, up 29% from $377M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Cormorant Asset Management deployed $86.4M of net new capital in Q3 2014, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.

On the sell side, the largest reduction was Omeros, an estimated $8.05M trimmed.

  • Cormorant Asset Management's largest Q3 2014 buy was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.
  • Cormorant Asset Management added most to Puma Biotechnology in Q3 2014, an estimated $61.6M increase.
  • Cormorant Asset Management's biggest Q3 2014 reduction was Omeros, cutting an estimated $8.05M.
  • Cormorant Asset Management fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $18.5M.
  • Cormorant Asset Management's ten largest holdings make up 57% of its $486M portfolio in Q3 2014.
  • Cormorant Asset Management opened 17 new positions and closed 6 in Q3 2014.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $486M.

Based on Cormorant Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.